Funding will support the development of AIM 101, a novel immuno-therapeutic agent for cancer

GAITHERSBURG, Maryland, July 17, 2014—NexImmune, an early stage biopharmaceutical company, today announced it has secured $3 million USD in financing led by New Enterprise Associates (NEA). Other investors include Pfizer Venture Investments and Amgen Ventures. In association with the financing, Jim Barrett of NEA and Janis Naeve of Amgen Ventures were named to NexImmune’s board of directors.

NexImmune is developing immunotherapy products from its proprietary Artificial IMmune (AIM™) nanotechnology. The AIM technology, which was first developed by Drs. Mathias Oelke and Jonathan Schneck at The Johns Hopkins University, has several potential applications for the treatment of cancer, autoimmune disorders, and infectious disease. Proceeds from this financing will be used to support pre-clinical development of the company’s first product, AIM 101, an artificial Antigen Presenting Cell (aAPC) for the treatment of cancer.

"As a privately funded early stage company, we made significant progress moving the AIM technology closer to the clinic in an effective and efficient manner," said Dr. Kenneth Carter, NexImmune’s Chief Executive Officer. "This expanded institutional financing will allow us to accelerate the development of what we believe will be the first of a series of novel and effective immunotherapies based on the AIM technology. I also welcome and look forward to working closely with our new board members and investors, whose expertise will be of great value to NexImmune’s progress.”

"We are pleased to provide NexImmune with this critical funding," said Dr. Barrett, General Partner, NEA. “Their AIM platform is potentially game-changing technology in the development of immunotherapies, and we are excited to partner with the company as they advance preclinical development of AIM 101.”

About NexImmune
NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM™) nanotechnology platform. Central to the AIM™ technology are artificial Antigen Presenting Cells (aAPC) that can be engineered to orchestrate a highly targeted immune attack directed toward specific foreign substances or cell types in the body. In preclinical studies, aAPCs have demonstrated potential utility as vaccines and therapeutic agents and can also be used for the development of diagnostic products. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer. For more information visit: www.neximmune.com